[1]
|
Rini, B.I., Campbell, S.C. and Escudier, B. (2009) Renal Cell Carcinoma. The Lancet, 373, 1119-1132. https://doi.org/10.1016/s0140-6736(09)60229-4
|
[2]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2018) Cancer Statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 7-30. https://doi.org/10.3322/caac.21442
|
[3]
|
Jani, C., Abdallah, N., Mouchati, C., Jani, R., Sharma, R., Bhatt, P., et al. (2022) Trends of Kidney Cancer Burden from 1990 to 2019 in European Union 15+ Countries and World Health Organization Regions. Scientific Reports, 12, Article No. 22368. https://doi.org/10.1038/s41598-022-25485-8
|
[4]
|
Xu, W., Liu, W., Xu, Y., Tian, X., Anwaier, A., Su, J., et al. (2021) Hexokinase 3 Dysfunction Promotes Tumorigenesis and Immune Escape by Upregulating Monocyte/Macrophage Infiltration into the Clear Cell Renal Cell Carcinoma Microenvironment. International Journal of Biological Sciences, 17, 2205-2222. https://doi.org/10.7150/ijbs.58295
|
[5]
|
Kimelberg, H.K. (1975) Alterations in Phospholipid-Dependent (Na++K+)-ATPase Activity Due to Lipid Fluidity. Effects of Cholesterol and Mg2+. Biochimica et Biophysica Acta (BBA)—Biomembranes, 413, 143-156. https://doi.org/10.1016/0005-2736(75)90065-6
|
[6]
|
Tjahjono, R., Phung, D., Gurney, H., Gupta, R., Riffat, F. and Palme, C.E. (2020) Thyroid Gland Metastasis from Renal Cell Carcinoma: A Case Series and Literature Review. ANZ Journal of Surgery, 91, 708-715. https://doi.org/10.1111/ans.16482
|
[7]
|
Atkins, M.B. and Tannir, N.M. (2018) Current and Emerging Therapies for First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma. Cancer Treatment Reviews, 70, 127-137. https://doi.org/10.1016/j.ctrv.2018.07.009
|
[8]
|
Ravi, P., Bakouny, Z., Schmidt, A. and Choueiri, T.K. (2020) Novel Therapeutic Approaches and the Evolution of Drug Development in Advanced Kidney Cancer. The Cancer Journal, 26, 464-470. https://doi.org/10.1097/ppo.0000000000000477
|
[9]
|
Robson, C.J., Churchill, B.M. and Anderson, W. (1969) The Results of Radical Nephrectomy for Renal Cell Carcinoma. Journal of Urology, 101, 297-301. https://doi.org/10.1016/s0022-5347(17)62331-0
|
[10]
|
Ljungberg, B., Cowan, N.C., Hanbury, D.C., Hora, M., Kuczyk, M.A., Merseburger, A.S., et al. (2010) EAU Guidelines on Renal Cell Carcinoma: The 2010 Update. European Urology, 58, 398-406. https://doi.org/10.1016/j.eururo.2010.06.032
|
[11]
|
Campbell, S.C., Novick, A.C., Belldegrun, A., Blute, M.L., Chow, G.K., Derweesh, I.H., et al. (2009) Guideline for Management of the Clinical T1 Renal Mass. Journal of Urology, 182, 1271-1279. https://doi.org/10.1016/j.juro.2009.07.004
|
[12]
|
Ghandour, R.A., Danzig, M.R. and McKiernan, J.M. (2015) Renal Cell Carcinoma: Risks and Benefits of Nephron-Sparing Surgery for T1 Tumors. Advances in Chronic Kidney Disease, 22, 258-265. https://doi.org/10.1053/j.ackd.2015.03.006
|
[13]
|
李云天, 董洋, 陈雨昂, 等. 减瘤手术对肾癌骨转移患者预后影响: 基于SEER数据库分析[J]. 临床泌尿外科杂志, 2024, 39(5): 374-381. https://doi.org/10.13201/j.issn.1001-1420.2024.05.002
|
[14]
|
陈益楠, 杨瑞. 肾癌根治术后切口感染的易感因素调查与预防措施分析[J]. 湖北科技学院学报(医学版), 2024, 38(2): 160-164. https://doi.org/10.16751/j.cnki.2095-4646.2024.02.0160
|
[15]
|
Van Poppel, H., Da Pozzo, L., Albrecht, W., Matveev, V., Bono, A., Borkowski, A., et al. (2007) A Prospective Randomized EORTC Intergroup Phase 3 Study Comparing the Complications of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma. European Urology, 51, 1606-1615. https://doi.org/10.1016/j.eururo.2006.11.013
|
[16]
|
Choueiri, T.K., Hessel, C., Halabi, S., Sanford, B., Michaelson, M.D., Hahn, O., et al. (2018) Cabozantinib versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival Update. European Journal of Cancer, 94, 115-125. https://doi.org/10.1016/j.ejca.2018.02.012
|
[17]
|
Motzer, R.J., Powles, T., Burotto, M., Escudier, B., Bourlon, M.T., Shah, A.Y., et al. (2022) Nivolumab plus Cabozantinib versus Sunitinib in First-Line Treatment for Advanced Renal Cell Carcinoma (Checkmate 9ER): Long-Term Follow-Up Results from an Open-Label, Randomised, Phase 3 Trial. The Lancet Oncology, 23, 888-898. https://doi.org/10.1016/s1470-2045(22)00290-x
|
[18]
|
Kim, W.Y. and Kaelin, W.G. (2004) Role of VHL Gene Mutation in Human Cancer. Journal of Clinical Oncology, 22, 4991-5004. https://doi.org/10.1200/jco.2004.05.061
|
[19]
|
Choueiri, T.K. and Kaelin, W.G. (2020) Targeting the HIF2-VEGF Axis in Renal Cell Carcinoma. Nature Medicine, 26, 1519-1530. https://doi.org/10.1038/s41591-020-1093-z
|
[20]
|
Organ, S.L. and Tsao, M. (2011) An Overview of the C-Met Signaling Pathway. Therapeutic Advances in Medical Oncology, 3, S7-S19. https://doi.org/10.1177/1758834011422556
|
[21]
|
Capozzi, M., De Divitiis, C., Ottaiano, A., von Arx, C., Scala, S., Tatangelo, F., et al. (2019) Lenvatinib, a Molecule with Versatile Application: From Preclinical Evidence to Future Development in Anti-Cancer Treatment. Cancer Management and Research, 11, 3847-3860. https://doi.org/10.2147/cmar.s188316
|
[22]
|
Choueiri, T.K., Eto, M., Motzer, R., De Giorgi, U., Buchler, T., Basappa, N.S., et al. (2023) Lenvatinib plus Pembrolizumab versus Sunitinib as First-Line Treatment of Patients with Advanced Renal Cell Carcinoma (CLEAR): Extended Follow-Up from the Phase 3, Randomised, Open-Label Study. The Lancet Oncology, 24, 228-238. https://doi.org/10.1016/s1470-2045(23)00049-9
|
[23]
|
Motzer, R.J., Hutson, T.E., Glen, H., Michaelson, M.D., Molina, A., Eisen, T., et al. (2015) Lenvatinib, Everolimus, and the Combination in Patients with Metastatic Renal Cell Carcinoma: A Randomised, Phase 2, Open-Label, Multicentre Trial. The Lancet Oncology, 16, 1473-1482. https://doi.org/10.1016/s1470-2045(15)00290-9
|
[24]
|
Albiges, L., Beckermann, K., Miller, W.H., Goh, J.C., Gajate, P., Harris, C.A., et al. (2023) Belzutifan plus Lenvatinib for Patients (pts) with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) after Progression on a PD-1/L1 and VEGF Inhibitor: Preliminary Results of Arm B5 of the Phase 1/2 KEYMAKER-U03B Study. Journal of Clinical Oncology, 41, 4553-4553. https://doi.org/10.1200/jco.2023.41.16_suppl.4553
|
[25]
|
Motzer, R.J., Schmidinger, M., Eto, M., Suarez, C., Figlin, R., Liu, Y., et al. (2023) LITESPARK-011: Belzutifan plus Lenvatinib vs Cabozantinib in Advanced Renal Cell Carcinoma after Anti-PD-1/PD-L1 Therapy. Future Oncology, 19, 113-121. https://doi.org/10.2217/fon-2022-0802
|
[26]
|
Bao, R., Qu, H., Li, B., Cheng, K., Miao, Y. and Wang, J. (2024) Knowledge Mapping of Immunotherapy for Breast Cancer: A Bibliometric Analysis from 2013 to 2022: A Correspondence. Human Vaccines & Immunotherapeutics, 20, Article ID: 2352278. https://doi.org/10.1080/21645515.2024.2352278
|
[27]
|
唐晓义, 刘婷, 张斌, 等. 树突状细胞免疫治疗转移性肾细胞癌临床转化的现状[J]. 中国肿瘤生物治疗杂志, 2013, 20(5): 609-617.
|
[28]
|
何立香. DC-CIK联合化疗治疗晚期NSCLC的临床研究[D]: [硕士学位论文]. 长沙: 中南大学, 2014.
|
[29]
|
惠丽娜, 范开席, 徐忠法. 肾细胞癌的治疗方法及应用现状[J]. 山东医药, 2015, 55(14): 102-103.
|
[30]
|
张澎, 张静, 刘亮, 等. CIK治疗转移性肾癌的临床疗效评价及预后影响因素分析[J]. 中国肿瘤临床, 2012, 39(10): 732-735.
|
[31]
|
Yamamoto, S., Nakayama, T., Seki, H., Kawada, C., Fukuhara, H., Karashima, T., et al. (2021) Sunitinib with Photoirradiation-Mediated Reactive Oxygen Species Generation Induces Apoptosis of Renal Cell Carcinoma Cells. Photodiagnosis and Photodynamic Therapy, 35, Article ID: 102427. https://doi.org/10.1016/j.pdpdt.2021.102427
|
[32]
|
Siva, S., Kothari, G., Muacevic, A., Louie, A.V., Slotman, B.J., Teh, B.S., et al. (2017) Radiotherapy for Renal Cell Carcinoma: Renaissance of an Overlooked Approach. Nature Reviews Urology, 14, 549-563. https://doi.org/10.1038/nrurol.2017.87
|
[33]
|
Tunio, M.A., Hashmi, A. and Rafi, M. (2010) Need for a New Trial to Evaluate Postoperative Radiotherapy in Renal Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials. Annals of Oncology, 21, 1839-1845. https://doi.org/10.1093/annonc/mdq028
|
[34]
|
Lim, S.H., Hwang, I.G., Ji, J.H., Oh, S.Y., Yi, J.H., Lim, D.H., et al. (2016) Intrinsic Resistance to Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Asia-Pacific Journal of Clinical Oncology, 13, 61-67. https://doi.org/10.1111/ajco.12465
|
[35]
|
Li, S., Yang, J., Wang, J., Gao, W., Ding, Y., Ding, Y., et al. (2018) Down-Regulation of miR-210-3p Encourages Chemotherapy Resistance of Renal Cell Carcinoma via Modulating ABCC1. Cell & Bioscience, 8, Article No. 9. https://doi.org/10.1186/s13578-018-0209-3
|
[36]
|
van der Mijn, J.C., Mier, J.W., Broxterman, H.J. and Verheul, H.M. (2014) Predictive Biomarkers in Renal Cell Cancer: Insights in Drug Resistance Mechanisms. Drug Resistance Updates, 17, 77-88. https://doi.org/10.1016/j.drup.2014.10.003
|
[37]
|
Long, Q., Du, Y., Liu, X., Li, X. and He, D. (2015) miR-124 Represses FZD5 to Attenuate P-Glycoprotein-Mediated Chemo-Resistance in Renal Cell Carcinoma. Tumor Biology, 36, 7017-7026. https://doi.org/10.1007/s13277-015-3369-3
|
[38]
|
Wang, Z., An, H., Hou, D., Wang, M., Zeng, X., Zheng, R., et al. (2019) Addressable Peptide Self-Assembly on the Cancer Cell Membrane for Sensitizing Chemotherapy of Renal Cell Carcinoma. Advanced Materials, 31, e1807175. https://doi.org/10.1002/adma.201807175
|